Skip to Main content Skip to Navigation
Journal articles

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

Aurélien Amiot 1 Mélanie Serrero 2 Laurent Peyrin-Biroulet 3 Jérome Filippi 4 Benjamin Pariente 5 Xavier Roblin 6 Anthony Buisson 7 Carmen Stefanescu 8 Caroline Trang-Poisson 9 Romain Altwegg 10 Philippe Marteau 11 Thibaud Vaysse 12 Anne Bourrier 13 Stephane Nancey 14 David Laharie 15 Matthieu Allez 16 Guillaume Savoye 17, 18, 19, 20 Jacques Moreau 21 Lucine Vuitton 22 Stephanie Viennot 23 Guillaume Bouguen 24 Vered Abitbol 25 Mathurin Fumery 26 Charlotte Gagniere 27 Yoram Bouhnik 28 Groupe d'Etude Thérapeutique Des Affections Getaid 29
Complete list of metadatas

https://hal-normandie-univ.archives-ouvertes.fr/hal-02362791
Contributor : Sabine Douville <>
Submitted on : Thursday, November 14, 2019 - 9:34:45 AM
Last modification on : Sunday, October 25, 2020 - 7:07:10 AM

Identifiers

Citation

Aurélien Amiot, Mélanie Serrero, Laurent Peyrin-Biroulet, Jérome Filippi, Benjamin Pariente, et al.. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Alimentary Pharmacology & Therapeutics (Suppl), 2019, 50 (1), pp.40-53. ⟨10.1111/apt.15294⟩. ⟨hal-02362791⟩

Share

Metrics

Record views

382